Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 18:keaf488.
doi: 10.1093/rheumatology/keaf488. Online ahead of print.

Relationship of radiographic progression status to low disease activity in patients with psoriatic arthritis receiving secukinumab treatment for two years

Philip J Mease  1 , Laura C Coates  2 , Corine Gaillez  3 , Alexis Shew  4 , Weibin Bao  4 , Christopher T Ritchlin  5
Affiliations

Relationship of radiographic progression status to low disease activity in patients with psoriatic arthritis receiving secukinumab treatment for two years

Philip J Mease et al. Rheumatology (Oxford). .

Abstract

Objective: To examine relationships between radiographic progression and achievement of low disease activity (LDA) or remission at week 104 in patients with psoriatic arthritis (PsA) receiving secukinumab.

Methods: This post hoc analysis included data from patients with active PsA enrolled in the phase 3 FUTURE 5 study (NCT02404350). Patients were pooled by treatment received at week 104 (secukinumab 300 mg with loading dose [LD], secukinumab 150 mg with LD, or secukinumab 150 mg without LD) and grouped by radiographic progression status. Radiographic progression was defined as change from baseline to week 104 in van der Heijde modified Total Sharp Score >0.5. Efficacy was assessed by achievement of minimal disease activity (MDA), very low disease activity (VLDA), and Disease Activity Index for Psoriatic Arthritis (DAPSA) LDA or remission. Demographics and clinical characteristics associated with radiographic progression at week 104 were identified by logistic regression analyses.

Results: Of the 541 patients included in this analysis, 457 (84.5%) were radiographic nonprogressors and 84 (15.5%) were radiographic progressors. Higher proportions of nonprogressors achieved MDA, VLDA, and DAPSA LDA and remission at week 104 than progressors. Radiographic progression at week 104 was associated with older age and higher baseline high-sensitivity C-reactive protein level, whereas nonprogression was associated with 300 mg secukinumab (vs 150 mg secukinumab without LD), no prior exposure to tumour necrosis factor inhibitors, and lower body mass index.

Conclusion: Patients without radiographic progression through 2 years of secukinumab treatment had greater achievement of LDA states at week 104 than patients with radiographic progression.

Trial registration: ClinicalTrials.gov; NCT02404350.

Keywords: Psoriatic arthritis; radiographic progression; secukinumab.

PubMed Disclaimer

Associated data